

Axicabtagene Ciloleuceil Chimeris Anitgen Receptor T Cell (CAR T) Therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma Quality Dashboard 2020/21



Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes	Reporting Periods			
															Q1	Q2	Q3	Q4
CARTLy01	Domain 2: Enhancing quality of life for people with long-term conditions	ITU transfer	Clinical outcome		Proportion of patients transferred to ITU from a ward within 60 minutes	Of those in the denominator, the number of patients transferred within 60 minutes	The total number of patients transferred to ITU from a ward in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better	Ward is defined as Inpatient unit or Oncology Day Ward	Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy02	Domain 1: Preventing people from dying prematurely	Survival	Clinical outcome		Proportion of patients who complete treatment and are alive 28 days after infusion	Of those in the denominator, the number of patients who are alive 28 days after infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy03	Domain 1: Preventing people from dying prematurely	Survival	Clinical outcome		Proportion of patients who complete treatment and are alive 1 year after first infusion	Of those in the denominator, the number of patients who are alive 1 year after first infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better		Apr 18 - Mar 19	N/A	N/A	Apr 19 - Mar 20
CARTLy04	Domain 1: Preventing people from dying prematurely	Survival	Clinical outcome		Proportion of patients who complete treatment and are alive 2 years after first infusion	Of those in the denominator, the number of patients who are alive 2 years after first infusion	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better		Apr 17 - Mar 18	N/A	N/A	Apr 18 - Mar 19
CARTLy05	Domain 3: Helping people to recover from episodes of ill health or following injury	Critical care	Clinical outcome		Total number of incidences of CRS (Cytokine-release syndrome) at grade 2 and above requiring level 3 critical care or PICU	Total number of incidences of CRS at grade 2 and above requiring level 3 critical care or PICU	N/A	Annual	Annual	Provider submitted data	Provider submitted data		Neutral		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy06	Domain 3: Helping people to recover from episodes of ill health or following injury	Critical care	Clinical outcome		Total number of incidences of CRES (cell-related encephalopathy syndrome) at grade 2 and above requiring level 3 critical care or PICU	Total number of incidences of CRES at grade 2 and above requiring level 3 critical care or PICU	N/A	Annual	Annual	Provider submitted data	Provider submitted data		Neutral		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy07	Domain 3: Helping people to recover from episodes of ill health or following injury	LoS	Clinical outcome		Average duration of admission for patients where an incidence of CRS (Cytokine-release syndrome) at grade 2 and above has occurred	Length of stay (in days) of all patients following admitted	The total number of patients admitted where an incidence of CRS at grade 2 or above has occurred in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Lower is better		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy08	Domain 3: Helping people to recover from episodes of ill health or following injury	LoS	Clinical outcome		Average duration of admission for patients where an incidence of CRES (cell-related encephalopathy syndrome) at grade 2 and above has occurred	Length of stay (in days) of all patients following admitted	The total number of patients admitted where an incidence of CRES at grade 2 or above has occurred in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Lower is better		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy09	Domain 1: Preventing people from dying prematurely	Mortality rate	Clinical outcome		3 month mortality rate	Of those in the denominator, the number of patients who die within 3 months of completing treatment	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Lower is better		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21
CARTLy10	Domain 3: Helping people to recover from episodes of ill health or following injury	LoS	Clinical outcome		Average length of stay of patients following treatment	Length of stay (in days) of all patients following completion of treatment	The total number of patients who complete treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Lower is better		Apr 19 - Mar 20	N/A	N/A	Apr 20 - Mar 21

Data collection has been approved by the Review of Central Returns - ROCR  
ROCR/OR/2230/001MAND